ATE478861T1 - Multizyklische verbindung und verwendungsverfahren - Google Patents

Multizyklische verbindung und verwendungsverfahren

Info

Publication number
ATE478861T1
ATE478861T1 AT07751460T AT07751460T ATE478861T1 AT E478861 T1 ATE478861 T1 AT E478861T1 AT 07751460 T AT07751460 T AT 07751460T AT 07751460 T AT07751460 T AT 07751460T AT E478861 T1 ATE478861 T1 AT E478861T1
Authority
AT
Austria
Prior art keywords
compounds
disease states
modulating
influencing
kinases
Prior art date
Application number
AT07751460T
Other languages
English (en)
Inventor
Victor Cee
Holly Deak
Stephanie Geuns-Meyer
Brian Hodous
Hanh Nho Nguyen
Philip R Olivieri
Vinod Patel
Karina Romero
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE478861T1 publication Critical patent/ATE478861T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steam Or Hot-Water Central Heating Systems (AREA)
AT07751460T 2006-02-24 2007-02-22 Multizyklische verbindung und verwendungsverfahren ATE478861T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77650706P 2006-02-24 2006-02-24
US11/709,994 US7868177B2 (en) 2006-02-24 2007-02-21 Multi-cyclic compounds and method of use
PCT/US2007/004700 WO2007100646A1 (en) 2006-02-24 2007-02-22 Multi-cyclic compounds and method of use

Publications (1)

Publication Number Publication Date
ATE478861T1 true ATE478861T1 (de) 2010-09-15

Family

ID=38242083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07751460T ATE478861T1 (de) 2006-02-24 2007-02-22 Multizyklische verbindung und verwendungsverfahren

Country Status (8)

Country Link
US (1) US7868177B2 (de)
EP (1) EP1994030B1 (de)
AT (1) ATE478861T1 (de)
AU (1) AU2007221294B2 (de)
CA (1) CA2643177C (de)
DE (1) DE602007008694D1 (de)
ES (1) ES2347489T3 (de)
WO (1) WO2007100646A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1751136B1 (de) * 2004-05-07 2014-07-02 Amgen Inc. Nitrogenierte heterozyklische derivate als proteinkinasemodulatoren und deren verwendung zur behandlung von angiogenese und krebs
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
WO2008057280A1 (en) * 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
GB0801416D0 (en) * 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶10抑制劑之吡衍生物
AR074343A1 (es) 2008-11-14 2011-01-12 Amgen Inc Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
WO2011058139A1 (en) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
EP2550266B1 (de) 2010-03-24 2018-05-09 Amitech Therapeutics Solutions, Inc. Heterozyklische verbindungen zur kinasehemmung
AU2012243226A1 (en) * 2011-03-01 2013-09-26 Npharmakon, Llc Use of N-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine and related compounds
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
CA3122383A1 (en) 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
AU2014304562B8 (en) 2013-08-08 2018-07-05 Galapagos Nv Thieno[2,3-c]pyrans as CFTR modulators
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US9963444B2 (en) 2014-05-19 2018-05-08 Northeastern University N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
WO2017047602A1 (ja) 2015-09-18 2017-03-23 科研製薬株式会社 ビアリール誘導体及びそれを含有する医薬
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
TW201838981A (zh) * 2017-03-17 2018-11-01 美商建南德克公司 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
US10689357B2 (en) 2018-05-08 2020-06-23 Northeastern University N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof
WO2020047518A1 (en) * 2018-08-30 2020-03-05 The Regents Of The University Of California Ire1 kinase inhibitors and uses thereof
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
CN112689528B (zh) 2018-09-12 2024-05-14 基因泰克公司 嘧啶基-杂芳氧基-萘基化合物和使用方法
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020142612A1 (en) 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
CA3128084A1 (en) * 2019-02-14 2020-08-20 Bridgene Biosciences, Inc. Fgfr inhibitors for the treatment of cancer
TWI756636B (zh) 2019-02-18 2022-03-01 美商建南德克公司 嘧啶并嘧啶化合物及使用方法
EP3983400B1 (de) 2019-06-11 2025-05-28 Genentech, Inc. Chinazolinylinverbindungen und verfahren zur verwendung
US20260234112A1 (en) * 2023-02-06 2026-08-13 Type6 Therapeutics, Inc. Compounds, compositions, and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69622183D1 (de) * 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111754A (pt) * 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
CA2454538A1 (en) 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
ATE446093T1 (de) 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
EP1517904A4 (de) 2002-05-23 2007-02-21 Merck & Co Inc Inhibitoren von mitotischem kinesin
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US7189729B2 (en) 2003-09-30 2007-03-13 Irm Llc Methods and compositions as protein kinase inhibitors
DE10349587A1 (de) 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
EP1751136B1 (de) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenierte heterozyklische derivate als proteinkinasemodulatoren und deren verwendung zur behandlung von angiogenese und krebs
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer

Also Published As

Publication number Publication date
ES2347489T3 (es) 2010-10-29
CA2643177A1 (en) 2007-09-07
DE602007008694D1 (de) 2010-10-07
WO2007100646A1 (en) 2007-09-07
EP1994030A1 (de) 2008-11-26
CA2643177C (en) 2011-06-14
AU2007221294A1 (en) 2007-09-07
US20070213325A1 (en) 2007-09-13
EP1994030B1 (de) 2010-08-25
AU2007221294B2 (en) 2011-08-25
US7868177B2 (en) 2011-01-11

Similar Documents

Publication Publication Date Title
DE602007008694D1 (de) Multizyklische verbindung und verwendungsverfahren
MX2009010517A (es) Moduladores de cinasa aurora y metodos de uso.
MY161884A (en) Aurora kinase modulators and method of use
MX2010010151A (es) Moduladores de cinasa aurora y metodo de uso.
MXPA06012613A (es) Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
MX2021007157A (es) Heteroarilamidas utiles como inhibidores de kif18a.
MX419368B (es) Heteroarilamidas utiles como inhibidores de kif18a
PH12021551409A1 (en) Kif18a inhibitors
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
CR11430A (es) 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpirimidin-2-aminas como inhibidores de cinasas janus
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
BRPI0509069A (pt) compostos de imidazol para o tratamento de distúrbios neurodegenerativos
UA113156C2 (xx) Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
BRPI0513405A (pt) tienopirimidinas úteis como inibidores de aurora quinase
WO2010017240A3 (en) Aurora kinase modulators and methods of use
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MA31336B1 (fr) Inhibiteurs de pi3k alpha a base de pyridopyrimidinone
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
EA201170344A1 (ru) Азаиндольные ингибиторы iap
UA93538C2 (en) Aurora kinase modulators and method of use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties